Karen A. Briggs
Overseas Federal Investigator / Consumer Safety Officer
ORA (Virginia Beach / European assignments)
Contamination control specialist with the highest citation concentration in her primary focus area — known for detecting cleaning residues on "cleaned" equipment, observing personnel behaviour in classified areas, and scrutinising smoke study acceptance criteria at European sterile facilities.
Inspection Approach
How Karen Inspects
Briggs brings a unique background to FDA inspection work — transitioning from an automobile assembly plant where she progressed from production floor to Quality Assurance, followed by radiological controls for the Department of Defense. This progression gives her practical manufacturing floor experience that informs how she evaluates personnel behaviour and contamination control in pharmaceutical facilities.
Her inspection focus on contamination control is the most concentrated of any investigator in this profile set (16 citations), followed by environmental monitoring (9 citations) and cleaning validation (4 citations). At Fareva Amboise in France, she identified that "cleaned" equipment still contained API residues from products manufactured months earlier, with many intervening products manufactured and distributed on the same equipment. She also documented smoke studies showing turbulent and stagnant air with non-unidirectional airflow patterns that the quality unit had approved regardless.
At Sentara Infusion Services, she documented non-sterile disinfecting agents used in ISO 5 areas, exposed wrists and hair during aseptic processing, and fungal species (Trichoderma sp. and Arthrographis sp.) in buffer room air samples. Her observation style is distinctly hands-on — she watches personnel in real time and physically inspects equipment surfaces for residues.
Citation Patterns
Top Focus Areas
Inspection History
Notable Inspections
Fareva Amboise
- Equipment cleaning not effective — residues of API from products manufactured months earlier detected on "cleaned" equipment, gaskets, and internal surfaces
- Quality unit approved Grade A filling line qualification despite smoke studies showing turbulent and non-unidirectional airflow
- Cleaning validation did not cover hardest-to-clean areas in manufacturing equipment
- Lapses in computer system controls and data integrity identified
- Deficient document control practices across manufacturing operations
Sentara Infusion Services
- Non-sterile disinfecting agents and cleaning wipes used in ISO 5 classified aseptic processing areas
- Personnel engaged in aseptic processing observed with exposed wrists and exposed hair
- Fungal air samples including Trichoderma sp. and Arthrographis sp. detected in buffer room
Baxter Oncology GmbH
- Sterile oncology drug manufacturing deficiencies identified during European inspection
RemedyRepack, Inc.
- Drug repackaging compliance deficiencies
Pre-Inspection Preparation
How to Prepare
- 1 Conduct a comprehensive review of contamination control strategy documents — ensure alignment with EU Annex 1 and FDA aseptic processing guidance.
- 2 Verify all disinfectants and cleaning agents used in classified areas are sterile-grade and documented as such in SOPs.
- 3 Audit gowning procedures and qualification — ensure personnel demonstrate proper technique with no exposed skin, hair, or wrists.
- 4 Review environmental monitoring data for trending and ensure fungal identification is performed on all recovered organisms.
- 5 Ensure cleaning validation protocols cover all hardest-to-clean areas — gaskets, seals, ports, dead legs — with documented justification.
- 6 Verify post-cleaning residue testing includes API-specific analytical methods for multi-product equipment.
- 7 Review smoke study documentation — ensure acceptance criteria are clearly defined and studies demonstrate unidirectional, laminar airflow.
- 8 Prepare personnel training records demonstrating competency in aseptic technique, gowning, and contamination control.
- 9 Verify Grade A/ISO 5 area qualification records are current and address all parameters (particles, airflow velocity, air changes, pressure differentials).
- 10 Review equipment changeover procedures for multi-product facilities — ensure cleaning verification between campaigns with residue testing.
- 11 Have qualification documentation ready for cleaning agents — demonstrating efficacy against facility-specific organisms.
Commonly Cited Regulations
Top CFR Citations
Frequently Paired With
Co-Investigators
Geographic Reach
Download Karen A. Briggs — FDA Investigator Profile
Enter your details once to unlock all Audit Hub resources. All future downloads are instant.
Leucine is the first AI-native platform built for pharmaceutical manufacturing. It unifies quality management, regulatory compliance, and production operations into one intelligent system that powers your entire drug manufacturing lifecycle from raw materials to patient delivery.
